Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s share price gapped up before the market opened on Friday after Wells Fargo & Company raised their price target on the stock from $4.50 to $5.50. The stock had previously closed at $3.94, but opened at $4.39. Wells Fargo & Company currently has an overweight rating on the stock. Maravai LifeSciences shares last traded at $4.4930, with a volume of 2,431,961 shares changing hands.
Separately, Wall Street Zen raised shares of Maravai LifeSciences from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $5.63.
Check Out Our Latest Report on Maravai LifeSciences
Hedge Funds Weigh In On Maravai LifeSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its holdings in Maravai LifeSciences by 64.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company's stock worth $4,015,000 after buying an additional 558,050 shares in the last quarter. Brummer Multi Strategy AB grew its holdings in Maravai LifeSciences by 66.0% in the 1st quarter. Brummer Multi Strategy AB now owns 759,743 shares of the company's stock worth $2,150,000 after buying an additional 302,036 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Maravai LifeSciences by 2.7% in the 1st quarter. Bank of New York Mellon Corp now owns 343,643 shares of the company's stock worth $973,000 after buying an additional 8,955 shares in the last quarter. General American Investors Co. Inc. grew its holdings in Maravai LifeSciences by 8.3% in the 1st quarter. General American Investors Co. Inc. now owns 1,716,193 shares of the company's stock worth $4,857,000 after buying an additional 130,877 shares in the last quarter. Finally, R Squared Ltd grew its holdings in Maravai LifeSciences by 76.0% in the 1st quarter. R Squared Ltd now owns 27,394 shares of the company's stock worth $78,000 after buying an additional 11,827 shares in the last quarter. 50.25% of the stock is owned by institutional investors.
Maravai LifeSciences Trading Up 14.1%
The business's 50 day moving average price is $3.33 and its two-hundred day moving average price is $3.39. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -5.00 and a beta of 0.62. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. The company had revenue of $49.87 million during the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. Equities analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.26 earnings per share for the current fiscal year.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.
Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
